Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Exane BNP Paribas Analyst Downgrades Expeditors International of Washington to Underperform

Elaine Mendonca by Elaine Mendonca
January 11, 2024
in Breaking News
0
Logistics Stock Market Today (2)
0
SHARES
21
VIEWS
Share on FacebookShare on Twitter

On January 11, 2024, Robert Joynson, an analyst at Exane BNP Paribas, made a distinctive move by downgrading Expeditors International of Washington (NYSE: EXPD) from Neutral to Underperform. Alongside this downgrade, Joynson set a price target of $116. The decision to downgrade was not taken lightly, as it was based on a comprehensive analysis that encompassed both quantitative and qualitative factors. Joynson carefully considered expected future growth, the current valuation of the stock, and macroeconomic trends. Consequently, the analyst believes that Expeditors International of Washington may face challenges and potentially underperform in the future.

[bs_slider_forecast ticker=”EXPD”]

EXPD Stock Analysis: Factors to Consider for Investment Decisions in 2024

On January 11, 2024, EXPD stock traded near the top of its 52-week range and above its 200-day simple moving average. The stock opened lower than its previous close, indicating a bearish sentiment at the start of the trading day. However, the slight price decrease of $0.09 may not necessarily indicate a significant change in the stock’s overall trajectory. Investors should consider various factors before making any investment decisions.

[stock_market_widget type=”chart” template=”basic” color=”#3946CE” assets=”EXPD” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” api=”yf”]

Expeditors International of Washington (EXPD) Stock Performance Analysis: January 11, 2024

EXPEDITORS INTERNATIONAL OF WASHINGTON (EXPD) STOCK PERFORMANCE ON JANUARY 11, 2024

Expeditors International of Washington (EXPD) is a global logistics company that provides freight forwarding and supply chain management services. As of January 11, 2024, the stock performance of EXPD can be analyzed based on the available information from CNN Money.

Total revenue for the past year was $17.07 billion, which represents a 3.32% increase compared to the previous year. However, in the third quarter of the same year, the total revenue remained flat at $2.19 billion.

Net income for the past year was $1.36 billion, reflecting a 4.1% decrease compared to the previous year. Similarly, in the third quarter of 2024, the net income further declined by 12.93% to $171.35 million.

Earnings per share (EPS) for the past year was $8.26, which remained flat compared to the previous year. However, in the third quarter of 2024, the EPS decreased by 10.84% to $1.16.

Investors may interpret these figures as a sign of concern, as the decrease in net income and EPS suggests a decline in profitability for EXPD. However, it is crucial to consider other factors such as market trends, industry competition, and the company’s overall financial stability before making any investment decisions.

It is important to note that stock performance is influenced by various factors, and a single day’s performance may not provide a complete picture of a company’s financial health. Investors should conduct thorough research and analysis, considering both short-term and long-term trends, before making any investment decisions.

Tags: EXPD
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Real Estate Investment Markets and money

W P Careys Strategic Sale of State of Andalusia Portfolio Positions Company for Growth

Biotechnology Markets and money

Emergent BioSolutions Safeguarding Public Health and National Security

Entertainment stock Trading

Redburn Atlantic Analyst Downgrades Paramount Global and Warner Bros Discovery

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com